Skip to content

Comparing the Use of Saline or Saline Plus Gentamycin in Nasal Irrigation to Treat Chronic Sinusitis in Children

Safety and Efficacy of Once Daily Intranasal Gentamycin Irrigation Versus Saline in the Treatment of Pediatric Chronic Sinusitis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00465530
Enrollment
40
Registered
2007-04-25
Start date
2007-03-31
Completion date
2010-03-31
Last updated
2013-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sinusitis

Brief summary

Healthy children may develop symptoms of chronic sinusitis such as chronic cough, chronic runny nose, nasal congestion, even headaches. Such symptoms may persist long after the child gets over other symptoms of a cold and commonly result in the prescription of oral antibiotics. The purpose of this study is to evaluate whether using saline alone or saline plus an antibiotic (gentamycin) to irrigate the nose directly once a day for 6 weeks is effective and safe for the treatment of the above named symptoms. Computerized axial tomography (CAT) scans and quality of life surveys will be used to compare the health of the sinuses before and after treatment, and scored to determine which of the two treatments, saline alone or saline with gentamycin, is more effective in the treatment of this condition. The study hypothesis is that intranasal saline irrigation will work as well as saline plus gentamycin, and that majority of the patients will experience significant improvement after a 6 week treatment period.

Detailed description

In the pediatric population, rhinosinusitis is a common concern resulting frequently in the frequent and unsuccessful prescription of systemic oral antibiotic therapy. Children typically experience an estimated 6-8 upper respiratory illnesses per year, usually viral, and only 13% are estimated to result in true sinusitis. True and chronic sinusitis, if not adequately treated, may result in long term symptoms including nasal airway obstruction, nasal congestion, persistent mucopurulent rhinorrhea, daytime and nocturnal cough, headaches, daytime fatigue, and even exacerbation or poor control of underlying asthma. A child's quality of life can be severely impacted as is their caretaker's due to days of missed school, frequency of doctor visits and courses of oral antibiotic therapy prescribed for the above mentioned symptoms, which ultimately result in the development of resistant organisms in addition to potential negative side effects associated with systemic oral antibiotic use. Intranasal saline irrigation is underutilized in the pediatric population, most likely due to the presumption that children will not cooperate nor tolerate the act of irrigation. Saline irrigation of the nose is an inexpensive and generally well tolerated treatment with very little side effects or risks. Rigorous data regarding the efficacy of saline irrigation has become more available in this past decade, with most studies demonstrating a clear improvement in patient quality of life as measured by various study instruments or outcome surveys. In our protocol, patients will be randomized to receive either saline alone or saline plus gentamycin in the solution form for nasal irrigation once daily for a six week treatment period. Weekly phone calls will be made to check for possible adverse events while patients are on treatment, and at the end of the treatment period another CAT scan will be performed to assess the status of the sinuses. Overall improvement will be determined based on the sinus status on the second CAT scan as well as the quality of life survey filled out by parents.

Interventions

DRUGSaline

Intranasal Saline

Intranasal irrigation

Sponsors

Julie Wei, MD
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
4 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

* Healthy children age 4-17 * History of Recurrent or Chronic Sinusitis * Definition: History must include \> 3 months of any or a combination of the following symptoms: * Nasal congestion/nasal airway obstruction * Rhinorrhea/Nasal discharge * Persistent cough (daytime) * Postnasal drip * Headache * Facial pain * Foul breath * Intermittent fever * Caregiver (proxy responsible) able to read and understand English * Has had at least 3 courses or a total of 21 days of oral antibiotic therapy for above symptoms in the previous 3 months * Child has a CT scan of the coronal sinus without contrast within two months prior to visit date, which demonstrates and opacification of a single or multiple, ipsilateral or bilateral sinuses.

Exclusion criteria

* Inability of caregiver to read and understand English * Mental retardation, cognitive impairment, or developmental delay * History of cystic fibrosis * History of immotile cilia syndrome * History of immune suppression/immune compromise * CT scan within past 4 weeks available for review at time of clinic visit which is entirely negative for evidence of sinus disease plus complete absence of any of the above symptoms * History of endoscopic sinus surgery * History of patient's inability to tolerate attempted nasal irrigation in the past 6 months * History of recent use of gentamycin intranasal irrigation or saline irrigation within the past 3 months * History of presence of nasal polyposis * History of allergic reaction of any kind to intravenous gentamycin or aminoglycosides in past medical history (for treatment of any infections)

Design outcomes

Primary

MeasureTime frameDescription
Change in Computed Tomography (CT) Score After TreatmentChange from Baseline to 6 WeeksChange in CT score reflects the Lund-Mackay staging system. Each sinus is scored separately and scores are determined for the right and the left side. The lowest score of 0 represents no opacification in the sinus. A score of 1 represents a partial opacification. A score of 2 represents complete opacification.
Change in Overall Quality of Life3 Weeks to Follow-Up (7 Weeks)Measured by Quality of Life Survey (SN-5). Scores ranged from 0 - 7. The higher the numerical score, the worse the problem.

Secondary

MeasureTime frameDescription
Change in Overall Quality of LifeBaseline to 3 WeeksMeasured by Quality of Life Survey (SN-5). Scores ranged from 0 - 7. The higher the numerical score, the worse the problem.

Countries

United States

Participant flow

Participants by arm

ArmCount
Saline Plus Gentamycin (Once Daily, 40 mL to Each Nostril)21
Saline (Once Daily, 40 mL to Each Nostril)19
Total40

Baseline characteristics

CharacteristicSaline Plus Gentamycin (Once Daily, 40 mL to Each Nostril)Saline (Once Daily, 40 mL to Each Nostril)Total
Age, Categorical
<=18 years
21 Participants19 Participants40 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
1 Participants0 Participants1 Participants
Race (NIH/OMB)
Black or African American
1 Participants0 Participants1 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants1 Participants3 Participants
Race (NIH/OMB)
White
17 Participants18 Participants35 Participants
Region of Enrollment
United States
21 participants19 participants40 participants
Sex: Female, Male
Female
12 Participants3 Participants15 Participants
Sex: Female, Male
Male
9 Participants16 Participants25 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
3 / 216 / 19
serious
Total, serious adverse events
0 / 210 / 19

Outcome results

Primary

Change in Computed Tomography (CT) Score After Treatment

Change in CT score reflects the Lund-Mackay staging system. Each sinus is scored separately and scores are determined for the right and the left side. The lowest score of 0 represents no opacification in the sinus. A score of 1 represents a partial opacification. A score of 2 represents complete opacification.

Time frame: Change from Baseline to 6 Weeks

ArmMeasureGroupValue (MEAN)Dispersion
Saline (Once Daily, 40 mL to Each Nostril)Change in Computed Tomography (CT) Score After TreatmentLeft maxillary-.64 units on a scaleStandard Deviation 0.63
Saline (Once Daily, 40 mL to Each Nostril)Change in Computed Tomography (CT) Score After TreatmentRight maxillary-.5 units on a scaleStandard Deviation 0.65
Saline (Once Daily, 40 mL to Each Nostril)Change in Computed Tomography (CT) Score After TreatmentLeft anterior ethmoid-.79 units on a scaleStandard Deviation 0.7
Saline (Once Daily, 40 mL to Each Nostril)Change in Computed Tomography (CT) Score After TreatmentRight anterior ethmoid-.79 units on a scaleStandard Deviation 0.8
Saline (Once Daily, 40 mL to Each Nostril)Change in Computed Tomography (CT) Score After TreatmentLeft posterior ethmoid-.57 units on a scaleStandard Deviation 0.65
Saline (Once Daily, 40 mL to Each Nostril)Change in Computed Tomography (CT) Score After TreatmentRight posterior ethmoid-.64 units on a scaleStandard Deviation 0.63
Saline (Once Daily, 40 mL to Each Nostril)Change in Computed Tomography (CT) Score After TreatmentLeft sphenoid-.43 units on a scaleStandard Deviation 0.65
Saline (Once Daily, 40 mL to Each Nostril)Change in Computed Tomography (CT) Score After TreatmentRight sphenoid-.5 units on a scaleStandard Deviation 0.65
Saline (Once Daily, 40 mL to Each Nostril)Change in Computed Tomography (CT) Score After TreatmentLeft frontal-.89 units on a scaleStandard Deviation 0.78
Saline (Once Daily, 40 mL to Each Nostril)Change in Computed Tomography (CT) Score After TreatmentRight frontal-.8 units on a scaleStandard Deviation 0.63
Saline (Once Daily, 40 mL to Each Nostril)Change in Computed Tomography (CT) Score After TreatmentLeft OMC-1 units on a scaleStandard Deviation 1.03
Saline (Once Daily, 40 mL to Each Nostril)Change in Computed Tomography (CT) Score After TreatmentRight OMC-.86 units on a scaleStandard Deviation 1.29
Saline (Once Daily, 40 mL to Each Nostril)Change in Computed Tomography (CT) Score After TreatmentTotal Score, left-4.07 units on a scaleStandard Deviation 3.25
Saline (Once Daily, 40 mL to Each Nostril)Change in Computed Tomography (CT) Score After TreatmentTotal score, right-3.86 units on a scaleStandard Deviation 3.11
Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril)Change in Computed Tomography (CT) Score After TreatmentLeft OMC-1.25 units on a scaleStandard Deviation 1
Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril)Change in Computed Tomography (CT) Score After TreatmentLeft maxillary-.63 units on a scaleStandard Deviation 0.5
Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril)Change in Computed Tomography (CT) Score After TreatmentRight sphenoid-.5 units on a scaleStandard Deviation 0.73
Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril)Change in Computed Tomography (CT) Score After TreatmentRight maxillary-.5 units on a scaleStandard Deviation 0.63
Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril)Change in Computed Tomography (CT) Score After TreatmentTotal Score, left-4.56 units on a scaleStandard Deviation 2.42
Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril)Change in Computed Tomography (CT) Score After TreatmentLeft anterior ethmoid-1.06 units on a scaleStandard Deviation 0.68
Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril)Change in Computed Tomography (CT) Score After TreatmentLeft frontal-.56 units on a scaleStandard Deviation 0.53
Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril)Change in Computed Tomography (CT) Score After TreatmentRight anterior ethmoid-.63 units on a scaleStandard Deviation 0.81
Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril)Change in Computed Tomography (CT) Score After TreatmentRight OMC-.88 units on a scaleStandard Deviation 1.02
Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril)Change in Computed Tomography (CT) Score After TreatmentLeft posterior ethmoid-.81 units on a scaleStandard Deviation 0.66
Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril)Change in Computed Tomography (CT) Score After TreatmentRight frontal-.22 units on a scaleStandard Deviation 0.44
Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril)Change in Computed Tomography (CT) Score After TreatmentRight posterior ethmoid-.75 units on a scaleStandard Deviation 0.68
Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril)Change in Computed Tomography (CT) Score After TreatmentTotal score, right-3.38 units on a scaleStandard Deviation 2.66
Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril)Change in Computed Tomography (CT) Score After TreatmentLeft sphenoid-.5 units on a scaleStandard Deviation 0.73
Primary

Change in Overall Quality of Life

Measured by Quality of Life Survey (SN-5). Scores ranged from 0 - 7. The higher the numerical score, the worse the problem.

Time frame: 3 Weeks to Follow-Up (7 Weeks)

ArmMeasureValue (MEAN)Dispersion
Saline (Once Daily, 40 mL to Each Nostril)Change in Overall Quality of Life.69 units on a scaleStandard Deviation 1.75
Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril)Change in Overall Quality of Life1.38 units on a scaleStandard Deviation 1.75
Secondary

Change in Overall Quality of Life

Measured by Quality of Life Survey (SN-5). Scores ranged from 0 - 7. The higher the numerical score, the worse the problem.

Time frame: Baseline to 3 Weeks

ArmMeasureValue (MEAN)Dispersion
Saline (Once Daily, 40 mL to Each Nostril)Change in Overall Quality of Life2.53 units on a scaleStandard Deviation 1.99
Saline Plus Gentamicin (Once Daily, 40 mL to Each Nostril)Change in Overall Quality of Life2.06 units on a scaleStandard Deviation 2.88

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026